BRIDGET CRAIN: Open Payments
NPI 1033660113 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,607 in 121 payments from 22 companies in 2025. Trend: 2023 $1,977 · 2024 $2,500 · 2025 $2,607
Food & beverage: $2,607
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $495 |
| GlaxoSmithKline, LLC. | 17 | $369 |
| Amgen Inc. | 15 | $225 |
| Grifols USA, LLC | 8 | $212 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $207 |
| Mallinckrodt Hospital Products Inc. | 9 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $152 |
| GENZYME CORPORATION | 6 | $127 |
| Merck Sharp & Dohme LLC | 5 | $99 |
| Viatris Specialty LLC | 4 | $81 |
Products named: TEZSPIRE, Prolastin-C Liquid, TRELEGY ELLIPTA, FASENRA, ACTHAR, DUPIXENT, NUCALA, OFEV.
Industry payments across AL — which companies pay providers there.
